Another rare disease startup is entering the market, this time backed by a group of executives who have been here before. Mendra, a new biotech led by former BioMarin and Escient Pharmaceuticals executives, has raised $82 million in a Series A round led by OrbiMed, 8VC, and 5AM Ventures. The company says the capital will…
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
You can find more information in our Privacy Policy and Privacy Policy.